{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "16279553",
  "DateCompleted": {
    "Year": "2005",
    "Month": "12",
    "Day": "07"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "12",
    "Day": "13"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "rus"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0372-9311",
      "JournalIssue": {
        "Issue": "5",
        "PubDate": {
          "Year": "2005",
          "Season": "Sep-Oct"
        }
      },
      "Title": "Zhurnal mikrobiologii, epidemiologii i immunobiologii",
      "ISOAbbreviation": "Zh Mikrobiol Epidemiol Immunobiol"
    },
    "ArticleTitle": "[Rhinovirus diseases: pathogenesis, diagnostics and treatment].",
    "Pagination": {
      "StartPage": "115",
      "EndPage": "121",
      "MedlinePgn": "115-21"
    },
    "Abstract": {
      "AbstractText": [
        "Contemporary data on human rhinovirus diseases and their pathogenesis are presented. Special attention is paid to complications which may be caused by rhinovirus infections in allergy-susceptible patients. Furthermore, approaches to the diagnostics and treatment of rhinovirus diseases are described. In particular, the advantages of molecular methods for the diagnostics of rhinovirus infection (based on the PCR) in comparison with cultural and immunochemical methods are pointed out. New investigations aimed at the development of specific antirhinovirus preparations--capsid-binding (Pleconaril), blocking the binding of the virus with cell receptors (ICAM, soluble) and inhibiting rhinovirus protease 3C--have been considered."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Fa\u012dzuloev",
        "ForeName": "E B",
        "Initials": "EB"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Nikonova",
        "ForeName": "A A",
        "Initials": "AA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Zverev",
        "ForeName": "V V",
        "Initials": "VV"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Russia (Federation)",
    "MedlineTA": "Zh Mikrobiol Epidemiol Immunobiol",
    "NlmUniqueID": "0415217",
    "ISSNLinking": "0372-9311"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Oxadiazoles"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Oxazoles"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Protease Inhibitors"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "RNA, Viral"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Viral Proteins"
    },
    {
      "RegistryNumber": "126547-89-5",
      "NameOfSubstance": "Intercellular Adhesion Molecule-1"
    },
    {
      "RegistryNumber": "9H4570Q89D",
      "NameOfSubstance": "pleconaril"
    },
    {
      "RegistryNumber": "EC 3.4.22.-",
      "NameOfSubstance": "Cysteine Endopeptidases"
    },
    {
      "RegistryNumber": "EC 3.4.22.28",
      "NameOfSubstance": "3C Viral Proteases"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "3C Viral Proteases"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "drug therapy"
      ],
      "DescriptorName": "Common Cold"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cysteine Endopeptidases"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Intercellular Adhesion Molecule-1"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Oxadiazoles"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Oxazoles"
    },
    {
      "QualifierName": [
        "diagnosis",
        "etiology",
        "therapy"
      ],
      "DescriptorName": "Picornaviridae Infections"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Polymerase Chain Reaction"
    },
    {
      "QualifierName": [
        "pharmacology",
        "therapeutic use"
      ],
      "DescriptorName": "Protease Inhibitors"
    },
    {
      "QualifierName": [
        "analysis"
      ],
      "DescriptorName": "RNA, Viral"
    },
    {
      "QualifierName": [
        "etiology"
      ],
      "DescriptorName": "Respiratory Hypersensitivity"
    },
    {
      "QualifierName": [
        "genetics",
        "isolation & purification"
      ],
      "DescriptorName": "Rhinovirus"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Solubility"
    },
    {
      "QualifierName": [
        "antagonists & inhibitors"
      ],
      "DescriptorName": "Viral Proteins"
    }
  ],
  "NumberOfReferences": "49"
}